Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTITUDE-HCM
2024-515125-28-00Phase 2Authorised
- Sponsor
- Imbria Pharmaceuticals
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing ninerafaxstat with placebo (2 arms). Primary endpoint: Change from baseline to Week 12 in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score. Planned start Dec 2025; status: authorised.
02
Drugs
ninerafaxstat
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2024-515125-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515125-28-00.